Table 2.
Autoantibody Frequency and co-existence with another autoantibody in the total cohort of 1673 patients.
| Autoantigen specificity1 | Autoantibody frequency n (%) | Co-Existing Autoantibody |
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| None | MSA |
MAA |
|||||||||||||||||||||
| Jo-1 | PL7 | PL12 | EJ | OJ | KS | Zo | Ha | SRP | Mi-2 | MDA5 | NXP2 | TIF1 | SAE | PMScl | Ku | Ro60 | La | snRNP | Other | ||||
| Jo-1 | 306 (18.7) | 245 | 1 | 4 | 38 | 13 | 15 | 5 | |||||||||||||||
| PL7 | 22 (1.3) | 57 (3.5) | 20 | 2 | |||||||||||||||||||
| PL12 | 12 (0.7) | 10 | 1 | 1 | |||||||||||||||||||
| EJ | 5 (0.3) | 2 | 1 | 2 | |||||||||||||||||||
| OJ | 10 (0.6) | 7 | (1) | 1 | 2 | ||||||||||||||||||
| KS | 3 (0.2) | 1 | 1 | 1 | |||||||||||||||||||
| Zo | 5 (0.3) | 5 | |||||||||||||||||||||
| Ha | 0 (0.0) | 0 | |||||||||||||||||||||
| SRP | 39 (2.4) | 38 | 1 | ||||||||||||||||||||
| Mi-2 | 88 (5.4) | 84 | 2 | 3 | |||||||||||||||||||
| MDA5 | 21 (1.3) | 21 | |||||||||||||||||||||
| NXP2 | 38 (2.3) | 32 | 2 | 3 | 1 | 2 | |||||||||||||||||
| TIF1 | 114 (7.0) | 105 | (1) | 3 | 5 | 2 | |||||||||||||||||
| SAE | 42 (2.6) | 41 | (1) | ||||||||||||||||||||
| PMScl | 129 (7.9) | 119 | 1 | 7 | 2 | 1 | |||||||||||||||||
| Ku | 24 (1.5) | 13 | (4) | (1) | (1) | (2) | (1) | 2 | 3 | ||||||||||||||
| Ro60 | 114 (7.0) | 19 | (38) | (2) | (1) | (2) | (2) | (3) | (3) | (7) | (2) | 30 | 19 | 5 | |||||||||
| La | 37 (2.3) | 1 | (13) | (1) | (2) | (30) | 2 | 0 | |||||||||||||||
| U1RNP/Sm | 124 (7.6) | 65 | (15) | (1) | (2) | (1) | (3) | (5) | (1) | (3) | (19) | (2) | 18 | ||||||||||
| Other | 54 (3.3) | 28 | (5) | (2) | (2) | (5) | 18 | 1 | |||||||||||||||
1Jo-1: histidyl-tRNA-synthetase, PL7: threonyl-tRNA-synthetase, PL12: alanyl-tRNA-synthetase, EJ: glycyl-tRNA-synthetase, OJ: isoleucyl-tRNA-synthetase, KS: asparaginyl-tRNA-synthetase, Zo: phenylalanyl-tRNA-synthetase, Ha tyrosyl-tRNA synthetase, SRP: signal recognition particle, Mi-2: nucleosome-remodelling deacetyalse complex, MDA5: melanoma differentiation-associated protein 5, NXP2: nuclear matrix protein 2, TIF1: transcriptional intermediary factor 1 alpha and/or gamma subunits, SAE: small ubiquitin-like modifier activating enzyme, PM/Scl: nucleolar macromolecular complex, Ku: DNA-binding nuclear protein complex, Ro60: SSA/Ro60, La: La/SSB, U1RNP/Sm: small nuclear RNA U1RNP and/or Sm subunits. Other includes U3RNP: small nuclear RNA U3 subunit, RNA Pol: RNA polymerase I/II/III, M2 mitochondrial antigen and topoisomerase I. Only three patients (0.18%) had more than one MSA (anti-Jo-1 coexistent with anti-OJ, anti-KS coexistent with anti-TIF1 and anti-KS coexistent with anti-SAE). Anti-PmScl is the only MAA that is not detected at all with a MSA.